Catch up on stories from the past week (and beyond) at the Slashdot story archive

 



Forgot your password?
typodupeerror
×
Medicine

Amazon To Stop Selling Seven Eyedrops After FDA Warning (nytimes.com) 22

Amazon said on Wednesday that it was removing seven eyedrops products from its website after the Food and Drug Administration warned the company that the eyedrops had not been recognized as safe and effective. From a report: The F.D.A. said in a letter to Andrew Jassy, Amazon's chief executive, on Monday that Amazon had violated federal regulations by selling the eyedrops, which claimed to help with problems including pink eye, dry eyes, eyestrain and floaters. "These products are especially concerning from a public health perspective," the F.D.A. letter said. "Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body's natural defenses."

The eyedrops named in the letter are: Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, TRP Natural Eyes Floaters Relief, and Manzanilla Sophia Chamomile Herbal Eye Drops. None of the eyedrops appeared to be available for purchase on Amazon on Wednesday morning. The company said in an emailed statement on Wednesday that "safety is a top priority."

This discussion has been archived. No new comments can be posted.

Amazon To Stop Selling Seven Eyedrops After FDA Warning

Comments Filter:
  • I smell a rat here. Can-C is an anti-cataract eyedrop identical to other eyedrops on the market and it's been out there for at least 15 years.
    • I smell a rat here. Can-C is an anti-cataract eyedrop identical to other eyedrops on the market and it's been out there for at least 15 years.

      The fine article is pay-walled so I only have what is in the summary to work with. The summary says pinkeye was a known risk for some of these eye drops, which could include Can-C, which could imply the eye drops weren't sufficiently sterilized and/or contained something that could breed an infection. Wasn't there something on Slashdot some time ago about people getting infections from a bad batch of nasal sprays or something? As I recall it was some really serious stuff too. We've had nasal sprays for

    • by EvilSS ( 557649 )
      Apparently not in the US. They are going after anything with n-acetyl-carnosine in it that was not submitted for approval for the treatment of cataracts or other conditions. Can-C tried to skirt the rules by listing it as an inactive ingredient. https://www.fda.gov/inspection... [fda.gov]

      We note that you list the NAC ingredient as an inactive ingredient or excipient on the label of your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products. However, your firm makes many therapeutic claims for NAC that cause it to be considered an active ingredient.4 For example, your website includes a blog post entitled, “The Benefits of N-Acetyl-Carnosine (NAC) for Your Eyes, Especially for Cataracts.” Many other examples of therapeutic claims related to NAC can be found in the various claims cited in this letter above which make it clear that NAC is intended to furnish pharmacological activity or other direct effect, including in the treatment of cataracts, and is thus an active ingredient. As previously stated, NAC is not a permitted active ingredient in Monograph M018 and treating or preventing cataracts is not a permitted indication in Monograph M018.

  • The FDA sent letters to CVS, Walgreens, and many other retailers and manufacturers.
    • That letter was because a production facility failed a safety inspection. This letter is because Amazon was selling products that were simply never approved for sale by the FDA.
  • Can't-C Eye Drops, Opaque 0 Eye Drops, OccludedMed, The Goodbye Eyes Company

Dynamically binding, you realize the magic. Statically binding, you see only the hierarchy.

Working...